The online version of this article (doi:10.1186/s12885-017-3094-y) contains supplementary material, which is available to authorized users.
The del1518 (rs3730485) polymorphism is an in/del variant in the MDM2 promoter P1. The variant is in complete linkage disequilibrium with MDM2 SNP309 (rs2279744) and has previously been found associated with an increased risk of colon cancer. In this study we assessed the impact of MDM2 del1518 on risk of ovarian and endometrial cancer.
Here, we genotyped del1518 in two large hospital-based series of patients diagnosed with ovarian (n = 1,385) or endometrial (n = 1,404) cancer and performed risk estimations as compared to the genotype distribution among 1,872 healthy female controls.
In overall analysis we observed no association between del1518 and risk of either ovarian or endometrial cancer. However, stratifying according to SNP309 status, we found the del1518 variant to be associated with a reduced risk of endometrial cancer among individuals carrying the SNP309TT genotype both in the dominant (OR = 0.64; 95% CI = 0.45 – 0.90) and the recessive model (OR = 0.80; 95% CI = 0.65 – 1.00). No such association was observed for ovarian cancer risk.
We found the MDM2 del1518 del variant to be associated with reduced risk of endometrial cancer among individuals carrying the MDM2 SNP309TT genotype.
Additional file 1: Table S1. MDM2 del158 genotype distribution in OC subgroups. (DOCX 17 kb)12885_2017_3094_MOESM1_ESM.docx
Additional file 2: Table S2. MDM2 del158 genotype distribution in EC subgroups. (DOCX 17 kb)12885_2017_3094_MOESM2_ESM.docx
Additional file 3: Table S3. MDM2 del158 genotype distribution among individuals with SNP309TT genitype in EC subgroups. (DOCX 15 kb)12885_2017_3094_MOESM3_ESM.docx
Additional file 4: Table S4. Raw data; genotypes for all individuals in study. (XLSX 118 kb)12885_2017_3094_MOESM4_ESM.xlsx
Landers JE, Cassel SL, George DL. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res. 1997;57:3562–8. PubMed
Gansmo LB, Vatten L, Romundstad P, Hveem K, Ryan BM, Harris CC, et al. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate, Oncotarget. 2016;7:28637-46.
Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, et al. The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer. Tumor Biol. 2016;37:10697-702.
Xie L, Sun Y, Chen T, Tian D, Li Y, Zhang Y, et al. Association between MDM2 SNP309 T > G polymorphism and the risk of bladder cancer: new data in a chinese population and an updated meta-analysis. OncoTargets Ther. 2015;8:3679–90.
- MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
Liv B. Gansmo
Mari Kyllesø Halle
Helga B. Salvesen
Per E. Lønning
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II